A clinical trial to study the effects of sharbat aftimoon in patients with high blood pressure.

Phase 2

Completed

• Conditions: Health Condition 1: null- Primary hypertension

• Registration Number: CTRI/2017/11/010656
• Lead Sponsor: ational Institute of Unani Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2017-03-21
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

1.Patients with stage- 1 primary hypertension

ranging systolic pressure140 to 159 mmHg and

diastolic pressure 90 to 99 mmHg.

2.Patients who will agree to sign the informed

consent form and follow up the protocol.

3.Age group: 30 to 65 years.

4.Gender:Either

Exclusion Criteria

1.Patients with cardiac arrhythmias (chronic atrial

fibrillation, frequent premature ventricular and

atrial contractions, ventricular or

supraven¬tricular tachycardia, tachycardia [heart

rate > 100 beats per minute]), atrioventricular

block.

2.Patients with malignant hypertension.

3.Patients with the episodes of marked arterial

hypotension (systolic BP < 90 mmHg)

4.Patients with the history of myocardial

infarction or acute cerebrovascular events,

stable angina or vasospastic angina, valvular

diseases.

5.Patients with the positive history of angioedema.

6.Patients with the history of chronic liver

disease, acute or chronic renal failure, Bronchial

asthma and Diabetes mellitus.

7.Lactating mothers and pregnant women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified